Cabaletta Bio, Inc. (CABA) Key Statistics & Financial Ratios

Cabaletta Bio, Inc. (CABA) — Price $2.49 HealthcareBiotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Cabaletta Bio, Inc. (CABA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells.

Stock Data

Price$2.49
Market Cap$406M
Enterprise Value$206.6M
Beta3.29
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-1.64
Price / Book1.86
P/S0.00
EV/EBITDA-1.17
EV/Sales0.00
EV/FCF-1.34
P/FCF-2.74
Earnings Yield-48.17%
FCF Yield-37.98%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-128.27%
Return on Assets-70.63%
Return on Invested Capital-78.51%
Return on Capital Employed-85.56%

Financial Health

Current Ratio5.79
Quick Ratio5.79
Cash Ratio5.64
Debt / Equity0.12
Debt / Assets10.02%
Net Debt / EBITDA1.13
Interest Coverage-80.94
Piotroski F-Score1
Altman Z-Score-4.65

Per-Share Data

Revenue per share0.00
Book Value per share1.39
Cash per share1.49
FCF per share-1.02
Tangible Book Value per share1.39
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy10
Hold2
Sell0
Strong Sell0
Total analysts12
Avg rating (1-5)0.83

Related companies: ALLO · AVIR · CAPR · EDIT · HUMA · IMMP · KYTX

Explore sector: Healthcare · Biotechnology

More sections of CABA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks